| Manufacturer ▼ | Drug Name | Indication | Stage | Status | Route of Administration | Drug Class |
|---|---|---|---|---|---|---|
| vTv Therapeutics Inc. | Azeliragon - STEADFAST | Mild Alzheimer’s disease | Phase 3 | Trial Discontinued | Oral | Neurology |
| vTv Therapeutics Inc. | Cadisegliatin | Type 2 Diabetes | Phase 2 | Trial Planned | Oral | Endocrinology |
| vTv Therapeutics Inc. | Azeliragon combined with stereotactic radiosurgery - (RAGE) | Brain metastasis from breast cancer | Phase 2 | Ongoing | Oral | Oncology |
| vTv Therapeutics Inc. | Azeliragon | Glioblastoma | Phase 2 | Ongoing | Oral | Oncology |
| vTv Therapeutics Inc. | Azeliragon | Mild Alzheimer’s disease with type 2 diabetes | Phase 2 | Trial Discontinued | Oral | Neurology |
| vTv Therapeutics Inc. | TTP273 - LOGRA | Type 2 Diabetes | Phase 2 | Trial Discontinued | Oral | Endocrinology |
| VYNE Therapeutics Inc. | FCD105 | Acne | Phase 3 | Trial Planned | Topical | N/A |
| VYNE Therapeutics Inc. | Repibresib Gel (VYN201) | Vitiligo | Phase 2b | Data Released | Topical | N/A |